Atypical free sialic acid storage disorder associated with tissue specific mosaicism of SLC17A5.

Free sialic acid storage disorder (FSASD) is a rare autosomal recessive lysosomal storage disease caused by pathogenic SLC17A5 variants with variable disease severity. We performed a multidisciplinary evaluation of an adolescent female with suspected lysosomal storage disease and conducted comprehensive studies to uncover the molecular etiology. The proband exhibited intellectual disability, a storage disease gestalt, and mildly elevated urine free sialic acid levels.

RidA proteins contribute to fitness of and by reducing 2AA stress and moderating flux to isoleucine biosynthesis.

Defining the physiological role of a gene product relies on interpreting phenotypes caused by the lack, or alteration, of the respective gene product. Mutations in critical genes often lead to easily recognized phenotypes that can include changes in cellular growth, metabolism, structure etc. However, mutations in many important genes may fail to generate an obvious defect unless additional perturbations are caused by medium or genetic background.

Egg Drop Syndrome 76 in a U.S. Broiler Breeder Flock.

A four-house broiler breeder farm of approximately 35-wk-old hens was diagnosed with egg drop syndrome (EDS'76) utilizing PCR and hemagglutination inhibition (HI) testing. Based on communication with local practitioners, the geographic area near where this flock was located had numerous EDS'76 cases in table egg layers at the time of diagnosis. An egg production drop was seen in the broiler breeder flock over a 7-day period, which prompted an investigation.

Monitoring clonal burden as an alternative to blast count for myelodysplastic neoplasm treatment response.

Accurate assessment of therapy response in myelodysplastic neoplasm (MDS) has been challenging. Directly monitoring mutational disease burden may be useful, but is not currently included in MDS response criteria, and the correlation of mutational burden and traditional response endpoints is not completely understood. Here, we used genome-wide and targeted next-generation sequencing (NGS) to monitor clonal and subclonal molecular disease burden in 452 samples from 32 patients prospectively treated in a clinical trial.